Exosens share falls below €59.15 and slips into the SBF 120 trough
The Bordeaux optronic company is declining mid-session in a lower-oriented Paris market. The movement extends Monday's decline and places it at the bottom of its index ranking.
A decline that brings the security below all its moving averages
The Exosens share is down 3.05% at €57.30, after losing 3.5% on Monday, placing it among the largest declines in the SBF 120, an index that is down 0.69% at the same time. The price is now below the 20-day MA at €59.15 (difference of 3.13%) as well as the 50-day MA at €59.38 (3.50%) and the 200-day MA at €60.25 (4.90%). The security thus falls back below its 200-day MA while it was still up 1.7% over three months. The support level at €54.15 is approximately 5.5% below the current price.
Over one week, the value declines 1%, but the quarter remains positive
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Today's decline occurs in a tense market, where the CAC 40 is down 0.66% and the DAX loses 1.5%, while French debt remains under scrutiny three days before Moody's examination of the country's rating. Over one month, Exosens loses 5.5%, but it maintains a 29.2% gain over one year. The RSI at 51 is neutral and signals neither overbought nor oversold conditions. The next event is the publication of third quarter 2026 revenue, expected on October 27.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
